850424-11-2 Usage
General Description
2-Chloro-6-methoxy-quinazoline is a chemical compound with the molecular formula C9H7ClN2O. It is a quinazoline derivative, which is a class of compounds that have potential pharmaceutical applications due to their diverse biological activities. This particular compound has a chlorine atom and a methoxy group attached to a quinazoline ring, giving it unique chemical properties. It may have potential applications in drug development, particularly in the field of medicinal chemistry, due to its structural features and potential pharmacological effects. Further research into its properties and potential uses may reveal its utility in various medicinal and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 850424-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,0,4,2 and 4 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 850424-11:
(8*8)+(7*5)+(6*0)+(5*4)+(4*2)+(3*4)+(2*1)+(1*1)=142
142 % 10 = 2
So 850424-11-2 is a valid CAS Registry Number.
850424-11-2Relevant articles and documents
INHIBITORS OF CYCLIN-DEPENDENT KINASES
-
Paragraph 00258, (2019/11/19)
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR
-
Page/Page column 183-184; 189, (2016/09/22)
The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory dis
NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
-
Page/Page column 96, (2012/06/30)
The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.